Developer docs
API playgroundTry for free, no card

Search company profiles

ShiraTronics

Full company profile

uuid0000pbc

Namestring
ShiraTronics
Legal namestring
ShiraTronics, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

ShiraTronics is a clinical-stage medical device company developing an implantable extracranial neuromodulation system (IEN) for the treatment of chronic migraine. Founded in 2019 and headquartered in St. Paul, Minnesota, with a wholly-owned Australian subsidiary (ShiraTronics Australia PTY LTD) used exclusively for clinical investigation, the company targets adults aged 22 or older with migraine for at least 12 months who experience 15 or more headache days per month and have not responded to conventional therapies including Botox. The product architecture consists of two fully implantable stimulators and leads placed beneath the skin near the occipital and supraorbital nerves, delivering mild electrical pulses to interrupt or change migraine pain signals; a handheld charger and headset support weekly recharging. ShiraTronics holds 27 issued US utility patents and one design patent covering the chronic migraine management system.

The clinical program includes the completed Australian RELIEV-CM pilot study (with positive 12-month follow-up data announced in September 2025) and the FDA-approved IDE RELIEV-CM2 pivotal trial, which completed enrollment in June 2026 with 300 participants across 28 US and Australian clinical sites and 146 implanted recipients. ShiraTronics received FDA Breakthrough Device Designation in February 2021 and is pursuing Premarket Approval (PMA), with a planned limited commercial launch post-approval. The American Medical Association CPT Editorial Panel accepted a dedicated five-code Category III set for bilateral supraorbital-occipital neurostimulator services, effective January 1, 2027.

ShiraTronics is pre-revenue with no commercial sales; the device is limited by US federal law to investigational use. Future revenue is expected from hardware sales of the implantable system and associated components following PMA clearance and a planned limited commercial launch targeting headache specialists, pain neurologists, and neurosurgeons. The company has raised $108 million cumulatively, including a $33M Series A (October 2019), a $5M Series A extension (August 2023), and a $66M Series B (October 2024) led by Norwest Venture Partners, with participation from USVP, Amzak Health, Treo Ventures, Aperture Ventures, Seroba, OSF Ventures, Global BioAccess Fund, and earlier investor LivaNova PLC.

Short descriptiontext

ShiraTronics is a clinical-stage medical device company developing a fully implantable extracranial neuromodulation system using bilateral supraorbital-occipital stimulation for chronic migraine patients unresponsive to conventional therapies, pursuing FDA PMA after completing its RELIEV-CM2 pivotal trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation devices, chronic migraine therapy, implantable neurostimulators, clinical-stage medtech, occipital nerve stimulation
Industry1 code
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Implantable Neuromodulation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Implantable Neuromodulation Device Sales
TypeHardware Sales
Description

Pre-commercial stage. The company is developing an implantable neurostimulation system for chronic migraine. Once FDA approved, the company plans a limited commercial launch, generating revenue through device sales and associated components (chargers, headsets).

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ShiraTronics develops an implantable extracranial neuromodulation therapy system — the ShiraTronics Migraine Therapy System — designed to treat chronic migraine through bilateral stimulation of the occipital and supraorbital nerves. The system consists of an implantable pulse generator, neurostimulation leads, and an externally worn controller that enables patient-directed therapy. The product is currently investigational and is being evaluated in the RELIEV-CM2 clinical study for refractory chronic migraine patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Positive 12-month follow-up data from RELIEV-CM Pilot Study demonstrating sustained reductions in headache frequency and severity, continued improvement in migraine-specific quality of life, and favorable safety profile
Product overview1 text field

ShiraTronics is a clinical-stage medical device company developing a unified product ecosystem centered on its ShiraTronics Migraine Therapy System, an implantable extracranial neuromodulation device for chronic migraine. The system consists of fully implantable stimulators and leads that deliver mild electrical pulses to occipital and supraorbital nerves, along with a handheld charger and headset for patient use. The clinical program includes the completed RELIEV-CM pilot study and the ongoing RELIEV-CM2 pivotal trial. The company has received FDA Breakthrough Device Designation and is pursuing Premarket Approval. The company raised $108M total as of 2026, with the most recent $66M Series B in October 2024.

Product and service1 record
1ShiraTronics Migraine Therapy System
CategoryImplantable Neuromodulation Devices
Description

An implantable extracranial neuromodulation therapy system consisting of an implantable pulse generator, occipital and supraorbital neurostimulation leads, and an externally worn patient controller. It is designed for specialist implantation in patients with refractory chronic migraine who have failed conventional pharmacologic therapy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Boston Scientific is a major neuromodulation player (Precision Spectra SCS, Vercise DBS) with established sales infrastructure into pain and neurosurgery specialists. Several ShiraTronics executives have direct Boston Scientific tenure, making it a relevant strategic comparability point.

TypeEmerging player
Description

Inspire Medical commercializes an implantable neurostimulation device (hypoglossal nerve stimulation) for obstructive sleep apnea. While the indication differs, Inspire is a relevant emerging-implantable-neurostim comparable on commercialization playbook, CPT code pathway, and unit economics.

TypeBroad incumbent
Description

Medtronic is the largest player in implantable neurostimulation (SCS, DBS, targeted drug delivery) and is the source of multiple ShiraTronics leaders including the VP of R&D/Manufacturing. It is the natural strategic acquirer or potential entrant into a migraine neuromodulation category.

TypeEmerging player
Description

Saluda Medical developed the Evoke closed-loop spinal cord stimulator and recently obtained FDA approval. It is an emerging neuromodulation implant peer at a similar stage of commercialization, providing useful comparables for valuation and adoption ramp.

TypeDirect peer
Description

Cefaly produces an external trigeminal nerve stimulation (e-TNS) device for migraine prevention. It is a direct competitor in the consumer- and clinician-facing migraine neuromodulation space and often referenced as the incumbent low-cost option ShiraTronics must displace.

TypeDirect peer
Description

Mainstay Medical developed ReActiv8, an implantable restorative neurostimulation system for mechanical chronic low back pain, and obtained FDA PMA approval. It is highly comparable on regulatory pathway, neuromodulation implant business model, and team overlap with ShiraTronics' VP of Regulatory, who authored ReActiv8's PMA.

TypeBroad incumbent
Description

Nevro is a publicly traded spinal cord stimulation (SCS) company with commercial neuromodulation sales force, payer relationships, and infrastructure that could in theory distribute or compete with migraine-focused neurostim. Relevant as a broad incumbent in implantable neurostimulation.

8Abbott (St. Jude Medical)
TypeBroad incumbent
Description

Abbott acquired Spinal Modulation (where ShiraTronics' co-founder was CTO) for over $500M, giving it Proclaim DRG neurostim and a path into neuromodulation. It is the most directly comparable incumbent relative to the founder's prior exit and the migraine indication.

TypeDirect peer
Description

Theranica develops Nerivio, a prescription neuromodulation device for acute and preventive migraine treatment. It is the closest direct competitor to ShiraTronics in the migraine-specific neuromodulation category, although delivered externally rather than implanted.

TypeDirect peer
Description

electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) device indicated for migraine and cluster headache. It competes for the same chronic and acute migraine neuromodulation patient pool that ShiraTronics targets with an implantable solution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ShiraTronics

Implantable Neuromodulation Medical Devicesshiratronics.com

ShiraTronics is a clinical-stage medical device company developing a fully implantable extracranial neuromodulation system using bilateral supraorbital-occipital stimulation for chronic migraine patients unresponsive to conventional therapies, pursuing FDA PMA after completing its RELIEV-CM2 pivotal trial.

What ShiraTronics does

ShiraTronics is a clinical-stage medical device company developing an implantable extracranial neuromodulation system (IEN) for the treatment of chronic migraine. Founded in 2019 and headquartered in St. Paul, Minnesota, with a wholly-owned Australian subsidiary (ShiraTronics Australia PTY LTD) used exclusively for clinical investigation, the company targets adults aged 22 or older with migraine for at least 12 months who experience 15 or more headache days per month and have not responded to conventional therapies including Botox. The product architecture consists of two fully implantable stimulators and leads placed beneath the skin near the occipital and supraorbital nerves, delivering mild electrical pulses to interrupt or change migraine pain signals; a handheld charger and headset support weekly recharging. ShiraTronics holds 27 issued US utility patents and one design patent covering the chronic migraine management system.

The clinical program includes the completed Australian RELIEV-CM pilot study (with positive 12-month follow-up data announced in September 2025) and the FDA-approved IDE RELIEV-CM2 pivotal trial, which completed enrollment in June 2026 with 300 participants across 28 US and Australian clinical sites and 146 implanted recipients. ShiraTronics received FDA Breakthrough Device Designation in February 2021 and is pursuing Premarket Approval (PMA), with a planned limited commercial launch post-approval. The American Medical Association CPT Editorial Panel accepted a dedicated five-code Category III set for bilateral supraorbital-occipital neurostimulator services, effective January 1, 2027.

ShiraTronics is pre-revenue with no commercial sales; the device is limited by US federal law to investigational use. Future revenue is expected from hardware sales of the implantable system and associated components following PMA clearance and a planned limited commercial launch targeting headache specialists, pain neurologists, and neurosurgeons. The company has raised $108 million cumulatively, including a $33M Series A (October 2019), a $5M Series A extension (August 2023), and a $66M Series B (October 2024) led by Norwest Venture Partners, with participation from USVP, Amzak Health, Treo Ventures, Aperture Ventures, Seroba, OSF Ventures, Global BioAccess Fund, and earlier investor LivaNova PLC.

ShiraTronics firmographics

Firmographics
Name
ShiraTronics
Legal name
ShiraTronics, Inc.
Website
https://shiratronics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
ShiraTronics is a clinical-stage medical device company developing a fully implantable extracranial neuromodulation system using bilateral supraorbital-occipital stimulation for chronic migraine patients unresponsive to conventional therapies, pursuing FDA PMA after completing its RELIEV-CM2 pivotal trial.
Ownership category
akta.pro rank

ShiraTronics industry classification

Industry
Product category
Implantable Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Neuromodulation devices
  • Chronic migraine therapy
  • Implantable neurostimulators
  • Clinical-stage medtech
  • Occipital nerve stimulation

Where ShiraTronics is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

ShiraTronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Implantable Neuromodulation Device Sales: Pre-commercial stage. The company is developing an implantable neurostimulation system for chronic migraine. Once FDA approved, the company plans a limited commercial launch, generating revenue through device sales and associated components (chargers, headsets).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

ShiraTronics product offering

Product offering

Core offering

ShiraTronics develops an implantable extracranial neuromodulation therapy system — the ShiraTronics Migraine Therapy System — designed to treat chronic migraine through bilateral stimulation of the occipital and supraorbital nerves. The system consists of an implantable pulse generator, neurostimulation leads, and an externally worn controller that enables patient-directed therapy. The product is currently investigational and is being evaluated in the RELIEV-CM2 clinical study for refractory chronic migraine patients.

Product overview

ShiraTronics is a clinical-stage medical device company developing a unified product ecosystem centered on its ShiraTronics Migraine Therapy System, an implantable extracranial neuromodulation device for chronic migraine. The system consists of fully implantable stimulators and leads that deliver mild electrical pulses to occipital and supraorbital nerves, along with a handheld charger and headset for patient use. The clinical program includes the completed RELIEV-CM pilot study and the ongoing RELIEV-CM2 pivotal trial. The company has received FDA Breakthrough Device Designation and is pursuing Premarket Approval. The company raised $108M total as of 2026, with the most recent $66M Series B in October 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • ShiraTronics Migraine Therapy System An implantable extracranial neuromodulation therapy system consisting of an implantable pulse generator, occipital and supraorbital neurostimulation leads, and an externally worn patient controller. It is designed for specialist implantation in patients with refractory chronic migraine who have failed conventional pharmacologic therapy.

Quantifiable outcome

  • Positive 12-month follow-up data from RELIEV-CM Pilot Study demonstrating sustained reductions in headache frequency and severity, continued improvement in migraine-specific quality of life, and favorable safety profile

Companies that use ShiraTronics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

ShiraTronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ShiraTronics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

ShiraTronics competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Boston Scientific is a major neuromodulation player (Precision Spectra SCS, Vercise DBS) with established sales infrastructure into pain and neurosurgery specialists. Several ShiraTronics executives have direct Boston Scientific tenure, making it a relevant strategic comparability point.
  • Medtronic: Medtronic is the largest player in implantable neurostimulation (SCS, DBS, targeted drug delivery) and is the source of multiple ShiraTronics leaders including the VP of R&D/Manufacturing. It is the natural strategic acquirer or potential entrant into a migraine neuromodulation category.
  • Nevro: Nevro is a publicly traded spinal cord stimulation (SCS) company with commercial neuromodulation sales force, payer relationships, and infrastructure that could in theory distribute or compete with migraine-focused neurostim. Relevant as a broad incumbent in implantable neurostimulation.
  • Abbott (St. Jude Medical): Abbott acquired Spinal Modulation (where ShiraTronics' co-founder was CTO) for over $500M, giving it Proclaim DRG neurostim and a path into neuromodulation. It is the most directly comparable incumbent relative to the founder's prior exit and the migraine indication.

Emerging players

  • Inspire Medical Systems: Inspire Medical commercializes an implantable neurostimulation device (hypoglossal nerve stimulation) for obstructive sleep apnea. While the indication differs, Inspire is a relevant emerging-implantable-neurostim comparable on commercialization playbook, CPT code pathway, and unit economics.
  • Saluda Medical: Saluda Medical developed the Evoke closed-loop spinal cord stimulator and recently obtained FDA approval. It is an emerging neuromodulation implant peer at a similar stage of commercialization, providing useful comparables for valuation and adoption ramp.

Direct peers

  • Cefaly Technology: Cefaly produces an external trigeminal nerve stimulation (e-TNS) device for migraine prevention. It is a direct competitor in the consumer- and clinician-facing migraine neuromodulation space and often referenced as the incumbent low-cost option ShiraTronics must displace.
  • Mainstay Medical: Mainstay Medical developed ReActiv8, an implantable restorative neurostimulation system for mechanical chronic low back pain, and obtained FDA PMA approval. It is highly comparable on regulatory pathway, neuromodulation implant business model, and team overlap with ShiraTronics' VP of Regulatory, who authored ReActiv8's PMA.
  • Theranica Bio-Electronics: Theranica develops Nerivio, a prescription neuromodulation device for acute and preventive migraine treatment. It is the closest direct competitor to ShiraTronics in the migraine-specific neuromodulation category, although delivered externally rather than implanted.
  • electroCore: electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) device indicated for migraine and cluster headache. It competes for the same chronic and acute migraine neuromodulation patient pool that ShiraTronics targets with an implantable solution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights8 records

Customer concentration

ShiraTronics social profiles

Digital presence

ShiraTronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ShiraTronics leadership team

Management profile

Number of profiles

ShiraTronics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ShiraTronics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ShiraTronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ShiraTronics

What does ShiraTronics do?

ShiraTronics develops an implantable extracranial neuromodulation therapy system — the ShiraTronics Migraine Therapy System — designed to treat chronic migraine through bilateral stimulation of the occipital and supraorbital nerves. The system consists of an implantable pulse generator, neurostimulation leads, and an externally worn controller that enables patient-directed therapy. The product is currently investigational and is being evaluated in the RELIEV-CM2 clinical study for refractory chronic migraine patients.

Is ShiraTronics a public or private company?

ShiraTronics is a private company. It is classified as venture growth investor backed and is currently operating.

When was ShiraTronics founded?

ShiraTronics was founded in 2019. It employs 11 to 50 people.

Where is ShiraTronics based?

ShiraTronics is headquartered in Minneapolis, United States, in the North America region.

How does ShiraTronics make money?

One revenue line is on record: implantable Neuromodulation Device Sales.

Who are ShiraTronics's main competitors?

Broad incumbents on record are Boston Scientific, Medtronic, Nevro and Abbott (St. Jude Medical). Emerging players are Inspire Medical Systems and Saluda Medical. Direct peers are Cefaly Technology, Mainstay Medical, Theranica Bio-Electronics and electroCore.

Does ShiraTronics have an API?

No public API is recorded for ShiraTronics.

What industry is ShiraTronics in?

ShiraTronics's product category is Implantable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireShiraTronics Completes Enrollment in RELIEV-CM2 Pivotal Trial of Implantable Extracranial Neuromodulation Systems (IENs) for Chronic MigraineShiraTronics announced completion of enrollment in its RELIEV-CM2 pivotal trial for an implantable neurostimulation system targeting chronic migraine, having enrolled 300 participants across 28 U.S. and Australian clinical sites with 146 participants receiving the implant. The American Medical Association CPT Editorial Panel independently accepted a dedicated five-code Category III set for bilateral supraorbital-occipital neurostimulator services, effective January 1, 2027, recognizing the procedure as a distinct clinical category. With FDA Breakthrough Device Designation since 2021 and $108M raised to date, the company is preparing for its planned readout sequence and intends to pursue Premarket Approval, followed by a limited commercial launch.TracxnTop Companies in Neurostimulation Devices for Pain (Oct, 2025)This article presents a ranking of top startups in the neurostimulation devices for pain sector, highlighting recent funding activities and company profiles. It details specific entities such as Saluda Medical, which raised $100 million in January 2025, and Nalu Medical, which secured $115 million in December 2023. The list also includes ShiraTronics and MyoScience, noting their respective development stages and therapeutic focuses.PR NewswireShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic MigShiraTronics released 12-month follow-up data from its RELIEV-CM Pilot Study showing sustained clinical benefit from its investigational implantable neuromodulation therapy for chronic migraine, with patients achieving an average 9.6-day reduction in both monthly headache days and migraine days, alongside continued improvement in quality of life and a favorable safety profile with no unanticipated adverse events. The company is actively enrolling participants in its larger RELIEV-CM2 pivotal trial for FDA premarket approval, with top-line results expected in 2026.PR NewswireShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic MigraineShiraTronics initiated its FDA-approved pivotal trial RELIEV-CM2 for chronic migraine, with first implants completed in the US and Australia. The study will implant up to 148 patients to assess long-term safety and efficacy. Early pilot data showed 80% of patients achieved a 50% reduction in migraine frequency.Pulse 2.0ShiraTronics: $66 Million (Series B) Raised To Develop Neurostimulation Therapies For Chronic Migraine PatientsShiraTronics closed a $66 million Series B led by Norwest Venture Partners to fund its FDA-approved RELIEV-CM2 trial for chronic migraine. The funding will support premarket approval and commercial launch of its implanted neuromodulation device, which targets treatment-resistant patients.YahooShiraTronics secures $66m in funding for implantable migraine deviceShiraTronics raised $66M in Series B funding to advance its implantable migraine device. The funds will support the RELIEV-CM2 clinical trial, a multi-centre, blinded, randomised, sham-controlled study for treatment-resistant chronic migraines. The trial is FDA-approved and led by Norwest Venture Partners.PR NewswireShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic MigraineShiraTronics closed a $66 million Series B financing led by Norwest Venture Partners. The funds will support its FDA-approved RELIEV-CM2 clinical trial and initial commercial launch of its implantable neuromodulation system for chronic migraine. The company also received Breakthrough Device designation from the FDA in 2021.VC News DailyShiraTronics Scores $66M in Series BShiraTronics, a clinical-stage medical device company developing neurostimulation therapies for chronic migraine patients, announced the closing of a $66 million Series B financing round. The round was led by Norwest Venture Partners with participation from Seroba, OSF Ventures, the Global BioAccess Fund, an undisclosed strategic investor, and returning investors U.S. Venture Partners, Amzak Health, Treo Ventures, and Aperture Venture Partners. This funding will support the company's continued development of neurostimulation therapies for chronic migraine sufferers.SecSEC FORM DShiraTronics, Inc. filed a Form D with the SEC to report an exempt offering of equity securities under Rule 506(b). The company reported total offering amounts exceeding $42 million with approximately $41.7 million already sold to 11 investors. This filing serves as a regulatory notice for the private placement of securities.PR NewswireShiraTronics, Inc. Welcomes New CEOShiraTronics appointed Robert Binney as CEO, succeeding Lynn Elliott on July 18, 2022. Binney previously led Alydia Health, which Organon acquired for $240 million. He will lead the company through clinical trials and commercialization.